Knappskog S - Search Results

1

The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE. Staalesen V, et al. Among authors: knappskog s. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4. doi: 10.1158/1078-0432.CCR-05-2822. Clin Cancer Res. 2006. PMID: 17062672

2

A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.

Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE. Knappskog S, et al. Genes Chromosomes Cancer. 2006 Dec;45(12):1155-63. doi: 10.1002/gcc.20379. Genes Chromosomes Cancer. 2006. PMID: 17001621

3

P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer.

Chrisanthar R, Knappskog S, Staalesen V, Lillehaug JR, Lønning PE. Chrisanthar R, et al. Among authors: knappskog s. Int J Cancer. 2007 Jun 15;120(12):2749. doi: 10.1002/ijc.22595. Int J Cancer. 2007. PMID: 17315192 Free article. No abstract available.

4

Breast cancer prognostication and prediction in the postgenomic era.

Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Lønning PE, et al. Among authors: knappskog s. Ann Oncol. 2007 Aug;18(8):1293-306. doi: 10.1093/annonc/mdm013. Epub 2007 Feb 21. Ann Oncol. 2007. PMID: 17317675 Free article. Review.

5

Mutations and polymorphisms of the p21B transcript in breast cancer.

Knappskog S, Chrisanthar R, Staalesen V, Børresen-Dale AL, Gram IT, Lillehaug JR, Lønning PE. Knappskog S, et al. Int J Cancer. 2007 Aug 15;121(4):908-10. doi: 10.1002/ijc.22777. Int J Cancer. 2007. PMID: 17443496 Free article.

6

New doctorial cancer research: germline genetic alterations affecting CDKN2A, MDM2, and CDKN1A in melanoma and breast cancer patients.

Knappskog S. Knappskog S. Crit Rev Oncog. 2007 Dec;13(3):261-2; discussion 263. doi: 10.1615/critrevoncog.v13.i3.30. Crit Rev Oncog. 2007. PMID: 18298387 No abstract available.

7

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE. Chrisanthar R, et al. Among authors: knappskog s. PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062. PLoS One. 2008. PMID: 18725978 Free PMC article.

8

Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

Jönsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringnér M, Lillehaug JR, Borg A, Lønning PE. Jönsson G, et al. Among authors: knappskog s. Clin Cancer Res. 2010 Jul 1;16(13):3356-67. doi: 10.1158/1078-0432.CCR-09-2509. Epub 2010 May 11. Clin Cancer Res. 2010. PMID: 20460471

9

Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.

Busch C, Geisler J, Knappskog S, Lillehaug JR, Lønning PE. Busch C, et al. Among authors: knappskog s. J Invest Dermatol. 2010 Oct;130(10):2514-6. doi: 10.1038/jid.2010.138. Epub 2010 May 27. J Invest Dermatol. 2010. PMID: 20505745 Free article. No abstract available.

10

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Berge EO, Knappskog S, Geisler S, Staalesen V, Pacal M, Børresen-Dale AL, Puntervoll P, Lillehaug JR, Lønning PE. Berge EO, et al. Among authors: knappskog s. Mol Cancer. 2010 Jul 1;9:173. doi: 10.1186/1476-4598-9-173. Mol Cancer. 2010. PMID: 20594292 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page